What if every
emergency department could stop bleeding faster?

What if every cancer center had access to life-sustaining platelet-based products?

What if platelet shortages during natural disasters could be eliminated?

Revolutionizing platelet-based therapies

Cellphire Therapeutics is developing next generation platelet-based therapeutics that are long-term shelf stable and could more rapidly treat bleeding.
‍
Until now, donated platelets had a shelf life of 5 to 7 days. But our patented technology allows us to freeze-dry platelets—stabilizing them—so they can last for years. Our investigational product, Thrombosomes®, once approved, could be given to anyone, anywhere, any time.

About our science

News

See all news

May 28, 2021

Cellphire Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of Thrombosomes in Bleeding Thrombocytopenic Patients

April 20, 2021

Cellphire Therapeutics Names Michael Gaffney as Company’s New CEO

April 5, 2021

Cellphire, Inc. Announces Rebrand to Cellphire Therapeutics, Inc.

Join Our Team

Discover yourself at Cellphire

We are looking for talented, innovative people to join us as we work to make a difference in the lives of patients. Learn more about the work we do, our team, and the benefits we have to offer.

Go to Careers